Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma
/in International Publications, Malignant Melanoma /von 2008-07-01 / J. Immunother. 2008 Jul-Aug;31(6):591-8IFN-producing killer dendritic cells contribute to the inhibitory effect of poly I:C on the progression of murine melanoma
/in International Publications, Malignant Melanoma /von 2008-07-01 / J. Immunother. 2008 Jul-Aug;31(6):555-62Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor
/in International Publications, Malignant Melanoma /von 2008-07-01 / J. Clin. Oncol. 2008 Jul;26(19):3235-41Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma
/in International Publications, Malignant Melanoma /von 2008-07-01 / Cancer Immunol. Immunother. 2008 Jul;57(7):1039-51Strategies to overcome obstacles to successful immunotherapy of melanoma
/in International Publications, Malignant Melanoma /von 2008-07-01 / Int J Immunopathol Pharmacol 2008 Jul-Sep;21(3):493-500Maximizing dendritic cell migration in cancer immunotherapy
/in Dendritic Cells, International Publications /von 2008-07-01 / Expert Opin Biol Ther 2008 Jul;8(7):865-74
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de